Search results for "risk assessment."

showing 10 items of 1342 documents

Is MRI imaging in pediatric age totally safe? A critical reprisal.

2017

Current radiological literature is strongly focussed on radiation imaging risks. Indeed, given there is a small but actual augment in cancer risk from exposure to ionizing radiation in children, it is important to understand what the risk of alternative techniques could be. We retrospectively review literature data concerning possible MR imaging risks, focussing on the biological effects of MR, sedation and gadolinium compound risks when dealing with infant patients. The main concerns can be summarized in: (1) Biological effects of non-ionizing electromagnetic fields (EMF) employed—whose mechanisms of interaction with human tissues are polarization, induced current, and thermal heating, res…

medicine.medical_specialtySedationContrast MediaRisk Assessment030218 nuclear medicine & medical imaging03 medical and health sciencesPatient safety0302 clinical medicineElectromagnetic FieldsRisk FactorsMedicineHumansRadiology Nuclear Medicine and imagingGeneral anaesthesiaNeuroradiologyPaediatric populationmedicine.diagnostic_testbusiness.industryRisk FactorInfant NewbornInfantMagnetic resonance imagingInterventional radiologyGeneral MedicineMRForeign BodiesForeign BodieMagnetic Resonance ImagingElectromagnetic FieldRadiological weaponRadiologyPatient SafetySafetymedicine.symptombusinessRisk assessmentNoise030217 neurology & neurosurgeryHumanLa Radiologia medica
researchProduct

Current insights into the German lipoprotein apheresis standard: PCSK9-inhibitors, lipoprotein apheresis or both?

2017

Abstract According to current European guidelines, lipid lowering therapy for progressive cardiovascular disease including cardiovascular events has to be focused on a target level for LDL-C. In contrast for Lp(a) a threshold has to be defined with respect to the method of measurement. However, due to new lipid lowering drug developments like PCSK9-inhibitors (PCSK-9-I) a therapeutic algorithm for patients with severe hypercholesterolemia or isolated Lipoprotein(a)-hyperlipoproteinemia with progressive cardiovascular disease may be necessary to manage the use of PCSK9-I, lipoprotein apheresis (LA) or both. The therapeutic approach for patients with homozygous familial hypercholesterolemia i…

medicine.medical_specialtySerine Proteinase InhibitorsDiseaseFamilial hypercholesterolemia030204 cardiovascular system & hematologyRisk AssessmentHyperlipoproteinemia Type II03 medical and health sciencesTherapeutic approach0302 clinical medicineRisk FactorsInternal medicineGermanyInternal MedicinemedicineHumans030212 general & internal medicinePCSK9 Inhibitorsbiologybusiness.industryPCSK9Anticholesteremic AgentsPCSK9 InhibitorsGeneral MedicineLipoprotein(a)Cholesterol LDLmedicine.diseaseCombined Modality TherapyEndocrinologyTreatment OutcomeCardiovascular Diseasesbiology.proteinCardiologyBlood Component Removallipids (amino acids peptides and proteins)Proprotein Convertase 9Cardiology and Cardiovascular MedicinebusinessLipoprotein apheresisBiomarkersLipoproteinLipoprotein(a)Atherosclerosis. Supplements
researchProduct

Clinical utility of novel biomarkers for cardiovascular disease risk stratification

2012

Over the past few decades, a number of coronary artery disease (CAD) and cardiovascular disease (CVD) risk factors have been identified. The predictive power of "conventional" risk factors have been validated by observational, prospective and intervention studies. Nevertheless, all attempts to exactly predict the individual risk for CAD have failed, biased by a large number of incorrectly risk-classified subjects. To improve cardiovascular (CV) risk prediction, a large number of genetic and/or non-genetic biomarkers have been discovered and tested against the "classical" risk factors for their power to predict CV risk. Only few of them had a significant improvement over the predictive model…

medicine.medical_specialtySettore MED/09 - Medicina InternaDiseaseIndividual riskRisk AssessmentCoronary artery diseaseInternal MedicinemedicineHumansRisk factorIntensive care medicinebusiness.industryBiomarkerCardiovascular riskAtherosclerosismedicine.diseaseIntervention studiesSurgeryCardiovascular DiseasesEmergency MedicineDisease riskPredictive powerObservational studybusinessPredictive powerBiomarkersInternal and Emergency Medicine
researchProduct

Exploration into Uric and Cardiovascular Disease: Uric Acid Right for heArt Health (URRAH) Project, A Study Protocol for a Retrospective Observationa…

2018

The relevance of cardiovascular role played by levels of serum uric acid is dramatically growing, especially as cardiovascular risk factor potentially able to exert either a direct deleterious impact or a synergic effect with other cardiovascular risk factors. At the present time, it still remains undefined the threshold level of serum uric acid able to contribute to the cardiovascular risk. Indeed, the available epidemiological case studies are not homogeneous, and some preliminary data suggest that the so-called "cardiovascular threshold limit" may substantially differ from that identified as a cut-off able to trigger the acute gout attack. In such scenario, there is the necessity to clar…

medicine.medical_specialtySettore MED/09 - Medicina InternaPrognosiEpidemiologyPopulationDiseaseHyperuricemia030204 cardiovascular system & hematologyRisk AssessmentCardiovascular disease; Epidemiology; Uric acid; Biomarkers; Cardiovascular Diseases; Humans; Hyperuricemia; Italy; Prognosis; Research Design; Retrospective Studies; Risk Assessment; Risk Factors; Uric Acid; Internal Medicine; Cardiology and Cardiovascular Medicine03 medical and health scienceschemistry.chemical_compound0302 clinical medicineRetrospective StudieRisk FactorsInternal medicineEpidemiologymedicineInternal MedicineHumansHyperuricemiaRisk factoreducationRetrospective Studies030203 arthritis & rheumatologyeducation.field_of_studybusiness.industryRisk FactorRetrospective cohort studyBiomarkermedicine.diseaseCardiovascular diseasePrognosisUric AcidchemistryItalyCardiovascular DiseasesResearch DesignUric acidCardiovascular disease; Epidemiology; Uric acidbusinessRisk assessmentCardiology and Cardiovascular MedicineBiomarkersHumanHigh blood pressurecardiovascular prevention : the official journal of the Italian Society of Hypertension
researchProduct

Subclinical Kidney Damage in Hypertensive Patients: A Renal Window Opened on the Cardiovascular System. Focus on Microalbuminuria

2017

The kidney is one of the major target organs of hypertension. Kidney damage represents a frequent event in the course of hypertension and arterial hypertension is one of the leading causes of end-stage renal disease (ESRD). ESRD has long been recognized as a strong predictor of cardiovascular (CV) morbidity and mortality. However, over the past 20 years a large and consistent body of evidence has been produced suggesting that CV risk progressively increases as the estimated glomerular filtration rate (eGFR) declines and is already significantly elevated even in the earliest stages of renal damage. Data was supported by the very large collaborative metaanalysis of the Chronic Kidney Disease …

medicine.medical_specialtySettore MED/09 - Medicina InternaRenal function030204 cardiovascular system & hematologyAsymptomatic03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicinemedicine030212 general & internal medicineSubclinical infectionSettore MED/14 - NefrologiaKidneyCreatinineProteinuriabusiness.industryArterial hypertension • Blood pressure • Glomerular filtration rate • Microalbuminuria • Proteinuria • Subclinical renal disease • Early kidney injury • Target organ damage • Cardiovascular disease • Cardiovascular risk assessmentmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolaremedicine.anatomical_structureEndocrinologychemistryCardiologyMicroalbuminuriamedicine.symptombusinessKidney disease
researchProduct

Special Article - Exercise-induced right ventricular injury or arrhythmogenic cardiomyopathy (ACM): The bright side and the dark side of the moon.

2020

There is still debate on the range of normal physiologic changes of the right ventricle or ventricular (RV) function in athletes. Genetic links to arrhythmogenic cardiomyopathy (ACM) are well-established. There is no current consensus on the importance of extensive exercise and exercise-induced injury to the RV. During the intensive exercise of endurance sports, the cardiac structures adapt to athletic load over time. Some athletes develop RV cardiomyopathy possibly caused by genetic predisposition, whilst others develop arrhythmias from the RV. Endurance sports lead to increased volume and pressure load in both ventricles and increased myocardial mass. The extent of volume increase and cha…

medicine.medical_specialtySports medicineVentricular Dysfunction RightCardiomyopathy030204 cardiovascular system & hematologyRisk AssessmentBoth ventriclesSudden cardiac death03 medical and health sciences0302 clinical medicineInternal medicinemedicineGenetic predispositionHumansGenetic Predisposition to Disease030212 general & internal medicineCardiomegaly Exercise-InducedPathologicalExerciseArrhythmogenic Right Ventricular DysplasiabiologyVentricular Remodelingbusiness.industryAthletesMyocardiummedicine.diseasebiology.organism_classificationAdaptation PhysiologicalFibrosismedicine.anatomical_structureDeath Sudden CardiacVentricleAthletesHeart Disease Risk FactorsCardiologyPhysical EnduranceVentricular Function RightCardiology and Cardiovascular MedicinebusinessProgress in cardiovascular diseases
researchProduct

High-Sensitivity C-Reactive Protein and Statin Initiation

2014

The assessment of cardiovascular risk and treatment of cardiovascular diseases are major public health issues worldwide. Inflammation is now recognized as a key regulatory process that links multiple risk factors for atherosclerosis. The substantial number of patients having cardiovascular events lack commonly established risk factors. The utility of high-sensitivity C-reactive protein (hsCRP), a circulating biomarker related to inflammation, may provide additional information in risk prediction. This review will consider the impact of hsCRP level on initiation of statin therapy.

medicine.medical_specialtyStatinmedicine.drug_classInflammationBioinformaticsMultiple risk factorsRisk AssessmentPredictive Value of TestsRisk FactorsmedicineHumanscardiovascular diseasesDyslipidemiasInflammationbiologybusiness.industryPublic healthC-reactive protein3. Good healthCirculating biomarkersC-Reactive ProteinTreatment OutcomeCardiovascular DiseasesPractice Guidelines as TopicPhysical therapybiology.proteinBiomarker (medicine)Statin therapyHydroxymethylglutaryl-CoA Reductase InhibitorsInflammation Mediatorsmedicine.symptomCardiology and Cardiovascular MedicinebusinessBiomarkersAngiology
researchProduct

Renal artery denervation for treating resistant hypertension: Definition of the disease, patient selection and description of the procedure

2012

Arterial hypertension is responsible for a significant burden of cardiovascular morbidity and mortality, worldwide. Although several rational and integrated pharmacological strategies are available, the control of high blood pressure still remains largely unsatisfactory. Failure to achieve effective blood pressure control in treated hypertensive patients may have a substantial impact on individual global cardiovascular risk, since it significantly increases the risk of developing hypertension-related macrovascular and microvascular complications. Arterial hypertension is arbitrarily defined as 'resistant' or 'refractory' when the recommended blood pressure goals (clinic blood pressure below…

medicine.medical_specialtySympathetic nervous systemSettore MED/09 - Medicina InternahypertensionDrug ResistanceFemoral arteryRisk AssessmentNephropathyPharmacotherapyRenal ArteryRisk Factorsmedicine.arteryInternal medicinemedicineInternal MedicineHumansArterial PressureRenal arterySympathectomyrenal artery denervationglobal cardiovascular riskantihypertensive therapyAntihypertensive AgentsSettore MED/14 - NefrologiaDenervationrefractory hypertensiontreatmentbusiness.industryPatient SelectionType 2 Diabetes Mellitusresistant hypertensionmedicine.diseaseSettore MED/11 - Malattie Dell'Apparato Cardiovascolaremedicine.anatomical_structureBlood pressureTreatment Outcomeresistant hypertension refractory hypertension renal artery denervation antihypertensive therapy global cardiovascular risk.resistant-hypertension; treatment; hypertensionCardiologyCatheter AblationHypertension treatment; Resistant-hypertension treatment; Antihypertensive Agents; Humans; Hypertension; Patient Selection; Renal Artery; Risk Assessment; Risk Factors; Sympathectomy; Treatment Outcome; Arterial Pressure; Catheter Ablation; Drug Resistance; Internal Medicine; Cardiology and Cardiovascular MedicinebusinessCardiology and Cardiovascular Medicineresistant-hypertension
researchProduct

The Metabolic Syndrome as a Prohypertensive State

2008

describe the ability of MetS to pre-dict the development of hypertension. The conclusions of this interesting study (CRISPS2) support the concept that the MetS, regardless of the criteria used to define it (NCEP-ATPIII or IDF), may be considered, at least in part, as a potentially reversible prohypertensive state.

medicine.medical_specialtyTime FactorsBlood PressureBioinformaticsRisk AssessmentBody Mass IndexRisk FactorsInternal medicinePrevalenceInternal MedicinemedicineHumansObesityProspective StudiesProportional Hazards ModelsMetabolic Syndromebusiness.industryAge Factorsnutritional and metabolic diseasesmedicine.diseaseHealth SurveysLipidsEndocrinologyCardiovascular DiseasesHypertensionHong KongMetabolic syndromebusinessAmerican Journal of Hypertension
researchProduct

RIPHeart (Remote Ischemic Preconditioning for Heart Surgery) Study: Myocardial Dysfunction, Postoperative Neurocognitive Dysfunction, and 1 Year Foll…

2018

Background Remote ischemic preconditioning ( RIPC ) has been suggested to protect against certain forms of organ injury after cardiac surgery. Previously, we reported the main results of RIPHeart (Remote Ischemic Preconditioning for Heart Surgery) Study, a multicenter trial randomizing 1403 cardiac surgery patients receiving either RIPC or sham‐ RIPC . Methods and Results In this follow‐up paper, we present 1‐year follow‐up of the composite primary end point and its individual components (all‐cause mortality, myocardial infarction, stroke and acute renal failure), in a sub‐group of patients, intraoperative myocardial dysfunction assessed by transesophageal echocardiography and the incidenc…

medicine.medical_specialtyTime FactorsMyocardial InfarctionNeurocognitive DisordersMyocardial Reperfusion InjuryNeuropsychological Tests030204 cardiovascular system & hematologyischemia/reperfusion injuryRisk Assessment03 medical and health sciencesCognition0302 clinical medicineDouble-Blind MethodRisk FactorsIschemiaGermanyMulticenter trialClinical StudiesClinical endpointHumansMedicineProspective Studies030212 general & internal medicineMyocardial infarctionCardiac Surgical ProceduresProspective cohort studyPropofolStrokeOriginal ResearchCardiovascular Surgerycardio‐vascular surgerybusiness.industryIncidenceProtective Factorsmedicine.diseaseSurgeryCardiac surgeryTreatment OutcomeIschemic Preconditioning MyocardialIschemic preconditioningremote ischemic preconditioningCardiology and Cardiovascular MedicinebusinessPropofolAnesthetics IntravenousEchocardiography Transesophagealmedicine.drug
researchProduct